AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis

Neurochemical Research

Volumn 41, Issue 3, 2016, Pages 544-553

  Perera, Nirma D ^a   Turner, Bradley J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ALS; AMPK; Energy; Metabolism; SOD1; TDP 43

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIMEBON; FUSED IN SARCOMA PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; RESVERATROL; TAR DNA BINDING PROTEIN;

AGING; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DISEASE COURSE; ENERGY METABOLISM; FATTY ACID OXIDATION; GLYCOLYSIS; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERMETABOLISM; LIPID METABOLISM; METABOLIC DISORDER; MOTONEURON; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ANIMAL; BRAIN; GENETICS; METABOLISM; MITOCHONDRION; SPINAL CORD;

AMP-ACTIVATED PROTEIN KINASES; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN; ENERGY METABOLISM; GLYCOLYSIS; HUMANS; LIPID METABOLISM; MITOCHONDRIA; MOTOR NEURONS; OXIDATIVE PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPINAL CORD;

EID: 84961197794     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-015-1665-3     Document Type: Article

References (117)

1. Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 14:248–264
2. Belanger M, Allaman I, Magistretti PJ (2011) Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14:724–738
3. Harris JJ, Jolivet R, Attwell D (2012) Synaptic energy use and supply. Neuron 75:762–777
4. Schonfeld P, Reiser G (2013) Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain. J Cereb Blood Flow Metab 33:1493–1499
5. van Hall G, Stromstad M, Rasmussen P, Jans O, Zaar M, Gam C, Quistorff B, Secher NH, Nielsen HB (2009) Blood lactate is an important energy source for the human brain. J Cereb Blood Flow Metab 29:1121–1129
6. Magistretti PJ, Pellerin L, Martin JL (1995) Brain energy metabolism: an integrated cellular perspective. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 657–670
7. Pellerin L, Magistretti PJ (2012) Sweet sixteen for ANLS. J Cereb Blood Flow Metab 32:1152–1166
8. Bouzier-Sore A-K, Voisin P, Canioni P, Magistretti PJ, Pellerin L (2003) Lactate is a preferential oxidative energy substrate over glucose for neurons in culture. J Cereb Blood Flow Metab 23:1298–1306
9. Smith D, Pernet A, Hallett WA, Bingham E, Marsden PK, Amiel SA (2003) Lactate: a preferred fuel for human brain metabolism in vivo. J cereb Blood Flow Metab 23:658–664
10. Bittar PG, Charnay Y, Pellerin L, Bouras C, Magistretti PJ (1996) Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain. J Cereb Blood Flow Metab 16:1079–1089
11. Foster DW (2012) Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J Clin Investig 122:1958–1959
12. Mitchell RW, On NH, Del Bigio MR, Miller DW, Hatch GM (2011) Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells. J Neurochem 117:735–746
13. Cahill GF Jr (2006) Fuel metabolism in starvation. Annu Rev Nutr 26:1–22
14. Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251–262
15. Oakhill JS, Scott JW, Kemp BE (2009) Structure and function of AMP-activated protein kinase. Acta Physiol (Oxford, England) 196:3–14
16. Li J, McCullough LD (2010) Effects of AMP-activated protein kinase in cerebral ischemia. J Cereb Blood Flow Metab 30:480–492
17. Lim MA, Selak MA, Xiang Z, Krainc D, Neve RL, Kraemer BC, Watts JL, Kalb RG (2012) Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. J Neurosci 32:1123–1141
18. Ofir M, Hochhauser E, Vidne BA, Freimark D, Arad M (2007) AMP-activated protein kinase: how a mistake in energy gauge causes glycogen storage. Harefuah 146:770–775, 813–814
19. Ronnett GV, Ramamurthy S, Kleman AM, Landree LE, Aja S (2009) AMPK in the brain: its roles in energy balance and neuroprotection. J Neurochem 109(Suppl 1):17–23
20. Poels J, Spasic MR, Callaerts P, Norga KK (2009) Expanding roles for AMP-activated protein kinase in neuronal survival and autophagy. BioEssays 31:944–952
21. Scarmeas N, Shih T, Stern Y, Ottman R, Rowland LP (2002) Premorbid weight, body mass, and varsity athletics in ALS. Neurology 59:773–775
22. Vaisman N, Lusaus M, Nefussy B, Niv E, Comaneshter D, Hallack R, Drory VE (2009) Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci 279:26–29
23. Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufrere B, Couratier P (2001) Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 74:328–334
24. Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P (1999) Nutritional status is a prognostic factor for survival in ALS patients. Neurology 53:1059–1063
25. Jawaid A, Murthy SB, Wilson AM, Qureshi SU, Amro MJ, Wheaton M, Simpson E, Harati Y, Strutt AM, York MK, Schulz PE (2010) A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler 11:542–548
26. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ (1996) Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 63:130–137
27. Bouteloup C, Desport JC, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A, Couratier P (2009) Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 256:1236–1242
28. Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10:75–82
29. O’Reilly EJ, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, Thun M, Park Y, Kolonel LN, Ascherio A (2013) Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 14:205–211
30. Desport J-C, Torny F, Lacoste M, Preux P-M, Couratier P (2005) Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neuro Degener Dis 2:202–207
31. Afifi AK, Aleu FP, Goodgold J, MacKay B (1966) Ultrastructure of atrophic muscle in amyotrophic lateral sclerosis. Neurology 16:475–481
32. Atsumi T (1981) The ultrastructure of intramuscular nerves in amyotrophic lateral sclerosis. Acta Neuropathol 55:193–198
33. Sasaki S, Iwata M (1996) Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis. Neurosci Lett 204:53–56
34. Siklos L, Engelhardt J, Harati Y, Smith RG, Joo F, Appel SH (1996) Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 39:203–216
35. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM (1999) Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann neurol 46:787–790
36. Bowling AC, Schulz JB, Brown RH Jr, Beal MF (1993) Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 61:2322–2325
37. Fujita K, Yamauchi M, Shibayama K, Ando M, Honda M, Nagata Y (1996) Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis. J Neurosci Res 45:276–281
38. Wiedemann FR, Winkler K, Kuznetsov AV, Bartels C, Vielhaber S, Feistner H, Kunz WS (1998) Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 156:65–72
39. Echaniz-Laguna A, Zoll J, Ponsot E, N’Guessan B, Tranchant C, Loeffler J-P, Lampert E (2006) Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: a temporal study in man. Exp Neurol 198:25–30
40. Perrin S (2014) Preclinical research: make mouse studies work. Nature 507:423–425
41. Nagano Y, Tsubaki T, Chase TN (1979) Endocrinologic regulation of carbohydrate metabolism. Amyotrophic lateral sclerosis and parkinsonism-dementia on guam. Arch Neurol 36:217–220
42. Pradat P-F, Bruneteau G, Gordon PH, Dupuis L, Bonnefont-Rousselot D, Simon D, Salachas F, Corcia P, Frochot V, Lacorte J-M, Jardel C, Coussieu C, Le Forestier N, Lacomblez L, Loeffler J-P, Meininger V (2010) Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:166–171
43. Reyes ET, Perurena OH, Festoff BW, Jorgensen R, Moore WV (1984) Insulin resistance in amyotrophic lateral sclerosis. J Neurol Sci 63:317–324
44. Gonzalez de Aguilar J-L, Dupuis L, Oudart H, Loeffler J-P (2005) The metabolic hypothesis in amyotrophic lateral sclerosis: insights from mutant Cu/Zn-superoxide dismutase mice. Biomed Pharmacother 59:190–196
45. Dalakas MC, Hatazawa J, Brooks RA, Di Chiro G (1987) Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann neurol 22:580–586
46. Dodge JC, Treleaven CM, Fidler JA, Tamsett TJ, Bao C, Searles M, Taksir TV, Misra K, Sidman RL, Cheng SH, Shihabuddin LS (2013) Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proc Natl Acad Sci USA 110:10812–10817
47. Murai A, Miyahara T, Tanaka T, Kaneko T, Sako Y, Kameyama M (1983) Abnormalities of lipoprotein and carbohydrate metabolism in degenerative diseases of the nervous system—motor neuron disease and spinocerebellar degeneration. Tohoku J Exp Med 139:365–376
48. Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ, Simpson E, Appel SH, York MK, Schulz PE (2010) ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol 17:733–739
49. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70:1004–1009
50. Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC (2011) Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 258:613–617
51. Chio A, Benzi G, Dossena M, Mutani R, Mora G (2005) Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 128:472–476
52. Lacomblez L, Doppler V, Beucler I, Costes G, Salachas F, Raisonnier A, Le Forestier N, Pradat PF, Bruckert E, Meininger V (2002) APOE: a potential marker of disease progression in ALS. Neurology 58:1112–1114
53. Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A (2008) Are statin medications safe in patients with ALS? Amyotroph Lateral Scler 9:223–228
54. Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J, Avigan M (2008) An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA’s spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf 17:1068–1076
55. Lindauer E, Dupuis L, Müller HP, Neumann H, Ludolph AC, Kassubek J (2013) Adipose tissue distribution predicts survival in amyotrophic lateral sclerosis. PLoS One 8:e67783
56. Barzilai N, Huffman DM, Muzumdar RH, Bartke A (2012) The critical role of metabolic pathways in aging. Diabetes 61:1315–1322
57. Felmus MT, Patten BM, Swanke L (1976) Antecedent events in amyotrophic lateral sclerosis. Neurology 26:167–172
58. Strickland D, Smith SA, Dolliff G, Goldman L, Roelofs RI (1996) Physical activity, trauma, and ALS: a case-control study. Acta Neurol Scand 94:45–50
59. Veldink JH, Kalmijn S, Groeneveld GJ, Titulaer MJ, Wokke JHJ, van den Berg LH (2005) Physical activity and the association with sporadic ALS. Neurology 64:241–245
60. Armon C (2007) Sports and trauma in amyotrophic lateral sclerosis revisited. J Neurol Sci 262:45–53
61. Longstreth WT, Nelson LM, Koepsell TD, van Belle G (1991) Hypotheses to explain the association between vigorous physical activity and amyotrophic lateral sclerosis. Med Hypotheses 34:144–148
62. Bello-Haas VD, Florence JM, Kloos AD, Scheirbecker J, Lopate G, Hayes SM, Pioro EP, Mitsumoto H (2007) A randomized controlled trial of resistance exercise in individuals with ALS. Neurology 68:2003–2007
63. Drory VE, Goltsman E, Reznik JG, Mosek A, Korczyn AD (2001) The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 191:133–137
64. Vergouts M, Marinangeli C, Ingelbrecht C, Genard G, Schakman O, Sternotte A, Calas A, Hermans E (2015) Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease. Metab Brain Dis. doi:10.1007/s11011-015-9706-9
65. Behan AT, Breen B, Hogg M, Woods I, Coughlan K, Mitchem M, Prehn JH (2013) Acidotoxicity and acid-sensing ion channels contribute to motoneuron degeneration. Cell Death Differ 20:589–598
66. Lim MA, Bence KK, Sandesara I, Andreux P, Auwerx J, Ishibashi J, Seale P, Kalb RG (2014) Genetically altering organismal metabolism by leptin-deficiency benefits a mouse model of amyotrophic lateral sclerosis. Hum Mol Genet 23:4995–5008
67. Eschbach J, Schwalenstocker B, Soyal SM, Bayer H, Wiesner D, Akimoto C, Nilsson A-C, Birve A, Meyer T, Dupuis L, Danzer KM, Andersen PM, Witting A, Ludolph AC, Patsch W, Weydt P (2013) PGC-1alpha is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet 22:3477–3484
68. Liang H, Ward WF, Jang YC, Bhattacharya A, Bokov AF, Li Y, Jernigan A, Richardson A, Van Remmen H (2011) PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve 44:947–956
69. Da Cruz S, Parone PA, Lopes VS, Lillo C, McAlonis-Downes M, Lee SK, Vetto AP, Petrosyan S, Marsala M, Murphy AN, Williams DS, Spiegelman BM, Cleveland DW (2012) Elevated PGC-1alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab 15:778–786
70. Zhao W, Varghese M, Yemul S, Pan Y, Cheng A, Marano P, Hassan S, Vempati P, Chen F, Qian X, Pasinetti GM (2011) Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1alpha) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol Neurodegener 6:51
71. Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Eschbach J, Rene F, Oudart H, Halter B, Huze C, Schaeffer L, Bouillaud F, Loeffler JP (2009) Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS One 4:e5390
72. Peixoto PM, Kim H-J, Sider B, Starkov A, Horvath TL, Manfredi G (2013) UCP2 overexpression worsens mitochondrial dysfunction and accelerates disease progression in a mouse model of amyotrophic lateral sclerosis. Mol Cell Neurosci 57:104–110
73. Pedersen WA, Mattson MP (1999) No benefit of dietary restriction on disease onset or progression in amyotrophic lateral sclerosis Cu/Zn-superoxide dismutase mutant mice. Brain Res 833:117–120
74. Hamadeh MJ, Rodriguez MC, Kaczor JJ, Tarnopolsky MA (2005) Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse. Muscle Nerve 31:214–220
75. Hamadeh MJ, Tarnopolsky MA (2006) Transient caloric restriction in early adulthood hastens disease endpoint in male, but not female, Cu/Zn-SOD mutant G93A mice. Muscle Nerve 34:709–719
76. Patel BP, Safdar A, Raha S, Tarnopolsky MA, Hamadeh MJ (2010) Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of ALS. PLoS One 5:e9386
77. Bhattacharya A, Bokov A, Muller FL, Jernigan AL, Maslin K, Diaz V, Richardson A, Van Remmen H (2012) Dietary restriction but not rapamycin extends disease onset and survival of the H46R/H48Q mouse model of ALS. Neurobiol Aging 33:1829–1832
78. Zhao W, Varghese M, Vempati P, Dzhun A, Cheng A, Wang J, Lange D, Bilski A, Faravelli I, Pasinetti GM (2012) Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PLoS One 7:e49191
79. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5:347–350
80. Ari C, Poff AM, Held HE, Landon CS, Goldhagen CR, Mavromates N, D’Agostino DP (2014) Metabolic therapy with Deanna protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PLoS One 9:e103526
81. Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla V, Klinder K, Schild L, Hengerer B, Ludolph AC, Dorner-Ciossek C, Kussmaul L (2006) Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x (+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride. J Pharmacol Exp Ther 316:189–199
82. Yacila G, Sari Y (2014) Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis. Curr Med Chem 21:3583–3593
83. Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch S, Henriques A, Boutillier A-L, Zoll J, Echaniz-Laguna A, Loeffler J-P, Rene F (2015) A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med 7:526–546
84. Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar J-L, Loeffler J-P (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 101:11159–11164
85. Zhao Z, Lange DJ, Voustianiouk A, MacGrogan D, Ho L, Suh J, Humala N, Thiyagarajan M, Wang J, Pasinetti GM (2006) A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci 7:29
86. Coughlan KS, Mitchem MR, Hogg MC, Prehn JH (2015) “Preconditioning” with latrepirdine, an adenosine 5′-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging 36:1140–1150
87. Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ (2011) Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One 6:e24189
88. Li J, Paulson JM, Ye FD, Sung M, Hollenberg AN, Rutkove SB (2012) Reducing systemic hypermetabolism by inducing hypothyroidism does not prolong survival in the SOD1-G93A mouse. Amyotroph Lateral Scler 13:372–377
89. Park J-H, Hong Y-H, Kim H-J, Kim S-M, Kim M-J, Park K-S, Sung J-J, Lee K-W (2007) Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. Neurosci Lett 413:265–269
90. Esposito E, Capasso M, di Tomasso N, Corona C, Pellegrini F, Uncini A, Vitaglione P, Fogliano V, Piantelli M, Sensi SL (2007) Antioxidant strategies based on tomato-enriched food or pyruvate do not affect disease onset and survival in an animal model of amyotrophic lateral sclerosis. Brain Res 1168:90–96
91. Amante DJ, Kim J, Carreiro ST, Cooper AC, Jones SW, Li T, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Ferrante RJ, Rusche J (2010) Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice. Amyotroph Lateral Scler 11:520–530
92. Dal Canto MC, Gurney ME (1995) Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 676:25–40
93. Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 18:3241–3250
94. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14:1105–1116
95. Bendotti C, Calvaresi N, Chiveri L, Prelle A, Moggio M, Braga M, Silani V, De Biasi S (2001) Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J Neurol Sci 191:25–33
96. Jung C, Higgins CMJ, Xu Z (2002) Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J Neurochem 83:535–545
97. Mattiazzi M, D’Aurelio M, Gajewski CD, Martushova K, Kiaei M, Beal MF, Manfredi G (2002) Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem 277:29626–29633
98. Damiano M, Starkov AA, Petri S, Kipiani K, Kiaei M, Mattiazzi M, Flint Beal M, Manfredi G (2006) Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J Neurochem 96:1349–1361
99. Higgins CMJ, Jung C, Ding H, Xu Z (2002) Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci 22:215
100. Browne SE, Yang L, DiMauro J-P, Fuller SW, Licata SC, Beal MF (2006) Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis 22:599–610
101. Miyazaki K, Masamoto K, Morimoto N, Kurata T, Mimoto T, Obata T, Kanno I, Abe K (2012) Early and progressive impairment of spinal blood flow-glucose metabolism coupling in motor neuron degeneration of ALS model mice. J Cereb Blood Flow Metab 32:456–467
102. Dupuis L, di Scala F, Rene F, de Tapia M, Oudart H, Pradat P-F, Meininger V, Loeffler J-P (2003) Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB J 17:2091–2093
103. Leclerc N, Ribera F, Zoll J, Warter JM, Poindron P, Lampert E, Borg J (2001) Selective changes in mitochondria respiratory properties in oxidative or glycolytic muscle fibers isolated from G93AhumanSOD1 transgenic mice. Neuromuscul disord 11:722–727
104. Fergani A, Oudart H, Gonzalez De Aguilar J-L, Fricker B, Rene F, Hocquette J-F, Meininger V, Dupuis L, Loeffler J-P (2007) Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J Lipid Res 48:1571–1580
105. Hussain G, Schmitt F, Henriques A, Lequeu T, Rene F, Bindler F, Dirrig-Grosch S, Oudart H, Palamiuc L, Metz-Boutigue M-H, Dupuis L, Marchioni E, Gonzalez De Aguilar J-L, Loeffler J-P (2013) Systemic down-regulation of delta-9 desaturase promotes muscle oxidative metabolism and accelerates muscle function recovery following nerve injury. PLoS One 8:e64525
106. Chiang P-M, Ling J, Jeong YH, Price DL, Aja SM, Wong PC (2010) Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc Natl Acad Sci USA 107:16320–16324
107. Stallings NR, Puttaparthi K, Dowling KJ, Luther CM, Burns DK, Davis K, Elliott JL (2013) TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. PLoS One 8:e71793
108. Shan X, Chiang P-M, Price DL, Wong PC (2010) Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci USA 107:16325–16330
109. Wang W, Li L, Lin W-L, Dickson DW, Petrucelli L, Zhang T, Wang X (2013) The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum Mol Genet 22:4706–4719
110. Xu Y-F, Gendron TF, Zhang Y-J, Lin W-L, D’Alton S, Sheng H, Casey MC, Tong J, Knight J, Yu X, Rademakers R, Boylan K, Hutton M, McGowan E, Dickson DW, Lewis J, Petrucelli L (2010) Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci 30:10851–10859
111. Huang EJ, Zhang J, Geser F, Trojanowski JQ, Strober JB, Dickson DW, Brown RH Jr, Shapiro BE, Lomen-Hoerth C (2010) Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Brain Pathol (Zurich, Switzerland) 20:1069–1076
112. Huang C, Tong J, Bi F, Wu Q, Huang B, Zhou H, Xia X-G (2012) Entorhinal cortical neurons are the primary targets of FUS mislocalization and ubiquitin aggregation in FUS transgenic rats. Hum Mol Genet 21:4602–4614
113. Perera ND, Sheean RK, Scott JW, Kemp BE, Horne MK, Turner BJ (2014) Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models. PLoS One 9:e90449
114. Sui Y, Zhao Z, Liu R, Cai B, Fan D (2014) Adenosine monophosphate-activated protein kinase activation enhances embryonic neural stem cell apoptosis in a mouse model of amyotrophic lateral sclerosis. Neural Regen Res 9:1770–1778
115. Liu Y-J, Lee L-M, Lai H-L, Chern Y (2015) Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Lett 589:432–439
116. Liu YJ, Ju TC, Chen HM, Jang YS, Lee LM, Lai HL, Tai HC, Fang JM, Lin YL, Tu PH, Chern Y (2015) Activation of AMP-activated protein kinase α1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. Hum Mol Genet 24:787–801
117. Mancuso R, del Valle J, Modol L, Martinez A, Granado-Serrano AB, Ramirez-Nunez O, Pallas M, Portero-Otin M, Osta R, Navarro X (2014) Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurother 11:419–432